Plain-English translation of NCT06930677 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment called NBGM200, which uses a minimally invasive procedure to target specific blood vessels in the knee that may be contributing to osteoarthritis pain. Researchers want to see if this treatment can safely reduce pain and improve how well your knee works. The study will follow 72 patients who have knee arthritis confirmed by MRI imaging.
Many people with knee arthritis have limited options beyond pain medications and physical therapy. This trial exists to see whether targeting the blood vessels involved in knee arthritis inflammation might offer a new way to relieve pain and help people stay active.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive a minimally invasive procedure called embolization, which involves a small catheter being guided to target specific blood vessels in your knee. After the procedure, you will be monitored and followed to see how well it works for your pain and knee function. The study team will track your progress and watch for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Belgium
Netherlands
Sponsor
Next Biomedical Co., Ltd.
Enrollment target
~72 participants
Started
April 2025
Primary completion
February 2027
Age range
50 Years and older
Last updated on clinicaltrials.gov in November 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.